Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.8100
- TODAY'S CHANGE (%)0.1100 (2.9730%)
- Bid / Lots3.8000/ 1
- Ask / Lots3.8100/ 3
- Open / Previous Close3.8500 / 3.7000
- Day Range
- 52 Week Range
- Volume127,470
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 7864 | 3.95 |
| 09:34 ET | 189 | 3.9 |
| 09:36 ET | 3561 | 3.9 |
| 09:38 ET | 928 | 3.98 |
| 09:39 ET | 100 | 3.92 |
| 09:41 ET | 481 | 3.8876 |
| 09:43 ET | 1026 | 3.86 |
| 09:45 ET | 2726 | 3.88 |
| 09:48 ET | 5736 | 3.91 |
| 09:50 ET | 1320 | 3.9098 |
| 09:52 ET | 100 | 3.91 |
| 09:54 ET | 850 | 3.93 |
| 09:56 ET | 900 | 3.9311 |
| 09:57 ET | 403 | 3.93 |
| 10:01 ET | 603 | 3.9 |
| 10:03 ET | 1677 | 3.9335 |
| 10:06 ET | 114 | 3.93 |
| 10:08 ET | 764 | 3.925 |
| 10:10 ET | 662 | 3.94 |
| 10:12 ET | 1300 | 3.91 |
| 10:14 ET | 850 | 3.88 |
| 10:15 ET | 300 | 3.88 |
| 10:17 ET | 1250 | 3.8701 |
| 10:19 ET | 900 | 3.86 |
| 10:21 ET | 950 | 3.84 |
| 10:24 ET | 100 | 3.84 |
| 10:26 ET | 2003 | 3.8476 |
| 10:28 ET | 400 | 3.81 |
| 10:30 ET | 1352 | 3.84 |
| 10:32 ET | 300 | 3.85 |
| 10:33 ET | 200 | 3.84 |
| 10:35 ET | 5884 | 3.84 |
| 10:37 ET | 400 | 3.86 |
| 10:39 ET | 1080 | 3.86 |
| 10:42 ET | 400 | 3.87 |
| 10:48 ET | 2600 | 3.86 |
| 10:50 ET | 300 | 3.85 |
| 10:51 ET | 3400 | 3.84 |
| 10:53 ET | 100 | 3.84 |
| 10:55 ET | 6474 | 3.84 |
| 10:57 ET | 200 | 3.84 |
| 11:00 ET | 9181 | 3.81 |
| 11:02 ET | 686 | 3.7971 |
| 11:04 ET | 5580 | 3.81 |
| 11:06 ET | 500 | 3.798 |
| 11:09 ET | 100 | 3.79 |
| 11:11 ET | 1810 | 3.77 |
| 11:15 ET | 857 | 3.77 |
| 11:18 ET | 300 | 3.7664 |
| 11:20 ET | 1002 | 3.77 |
| 11:26 ET | 200 | 3.76 |
| 11:27 ET | 112 | 3.76 |
| 11:29 ET | 1604 | 3.77 |
| 11:31 ET | 3000 | 3.7602 |
| 11:33 ET | 200 | 3.77 |
| 11:38 ET | 100 | 3.76 |
| 11:40 ET | 1927 | 3.77 |
| 11:42 ET | 489 | 3.76 |
| 11:44 ET | 1100 | 3.77 |
| 11:47 ET | 7924 | 3.79 |
| 11:49 ET | 3360 | 3.8 |
| 11:56 ET | 1199 | 3.81 |
| 12:00 ET | 1130 | 3.825 |
| 12:02 ET | 1357 | 3.81 |
Yesterday
Apr 4, 2024
DJ Kodiak Sciences Is Maintained at Neutral by UBS, from 11:28AM ET on Thursday Apr 04, 2024 by Dow Jones
11:28AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 194.4M | -0.8x | --- |
Atossa Therapeutics Inc | 190.5M | -6.9x | --- |
Outlook Therapeutics Inc | 189.5M | -2.2x | --- |
Boundless Bio Inc | 201.3M | -4.0x | --- |
Cardiff Oncology Inc | 200.3M | -4.7x | --- |
Design Therapeutics Inc | 206.2M | -3.2x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $194.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.45 |
EPS | $-4.97 |
Book Value | $5.06 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
